Navigation Links
STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
Date:11/28/2007

ANTONY, France, November 28 /PRNewswire-FirstCall/ -- The results of a study on children confirmed the efficacy of the ORALAIR(R) Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.

The phase III paediatric study, VO52.06, which was carried out on 280 patients in 5 European countries suffering from allergic rhino-conjunctivitis, fully met the main evaluation criterion by demonstrating a statistically significant reduction in symptoms, comparable to that observed in the VO34.04 adult study.

Based on this study, STALLERGENES will request the indication of the ORALAIR(R) Grasses market authorisation to be extended to children.

In addition, results of the first long term adult study (VO53) will be available by the end of the year.

STALLERGENES is confident in the commercial launch of ORALAIR(R) Grasses in Europe.

At the same time, as part of the Company's expansion in the US, the proposal for two phase III clinical studies in the US (adults and children), planned for 2009, was received favourably by the FDA and American experts. Talks with potential partners are ongoing.

All these items will be subject to an information meeting on 10 December 2007.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

Pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 18% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

STALLERGENES realised 2006 sales of EUR 126.5 million, primarily from European markets.

Stallergenes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code:
'/>"/>

SOURCE Stallergenes
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Blood Donations in U.S. Testing Positive for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... - Results From a Survey Conducted by UCB Assessing ... Countries , , - A third of ... impacts their enjoyment of the festive season, ... shopping for gifts, preparing holiday ... difficult to do, - Nearly ...
(Date:12/11/2009)... MA (12/11/2009) Boston College researchers have observed the ... first time and successfully harvested the elusive charges using ... solar power efficiency, the authors report in the current ... When light is captured in solar cells, it generates ... in order to snare these charges, the electrons must ...
(Date:12/11/2009)... Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" ... Dr. Alan Warrander to the role of Senior ... "Dr. Warrander will be responsible for the execution ... Dr. Brad Thompson, President and CEO of Oncolytics. ... a Phase 3 trial examining REOLYSIN in combination ...
(Date:12/10/2009)... National Eye Institute (NEI), a division of the National Institutes ... Inc. to help fund its development of a non-invasive, passive ... ... Salt Lake City, UT (PRWEB) December ... of the National Institutes of Health (NIH), awarded a $2.18 ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Elusive 'hot' electrons captured in ultra-thin solar cells 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3
... Accelerated Community Oncology,Research Network, Inc. (ACORN), ... clinical trial evaluating the efficacy of Nexavar(R) ... gemcitabine (Gemzar(R)) in patients,with metastatic breast cancer ... with bevacizumab (Avastin(R))., (Logo: http://www.newscom.com/cgi-bin/prnh/20071112/CLM151LOGO ...
... to Begin Later This Year - ... - Patient-Friendly (No Needles); No Preservatives - Stable at ... ... IRVING, Texas, Feb. 14 Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that ...
... GeoPharma, Inc. (Nasdaq:,GORX) announced record revenues of ... a 200% increase in sales sequentially, as it,reported ... periods ending,December 31, 2007., "We are pleased ... quarter of our 2008 fiscal year; it demonstrates ...
Other Biology Technology:Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx 2Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 2Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 4GeoPharma Announces Record Revenues in Third Quarter Results 2GeoPharma Announces Record Revenues in Third Quarter Results 3GeoPharma Announces Record Revenues in Third Quarter Results 4GeoPharma Announces Record Revenues in Third Quarter Results 5GeoPharma Announces Record Revenues in Third Quarter Results 6
(Date:12/11/2009)... how bacteria under stress collectively weigh and initiate different ... how humans make strategic decisions that affect their health, ... Their study, published this week in the early online ... Academy of Sciences , was accomplished when the scientists ... the complex interplay of genes and proteins that colonies ...
(Date:12/11/2009)... This release is available in French . ... have discovered a novel molecular mechanism that prevents cancer. ... Molecular Cell , scientists from the Universit de ... found that the SOCS1 molecule prevents the cancer-causing activity ... inflammation diseases such as Crohns, in smokers and people ...
(Date:12/11/2009)... growers, profits have traditionally been limited by ... growing seasons can be short. Thanks to ... are being introduced that offer growers the ... in economic bonuses for both producers and ... of blackberry called "primocane-fruiting", which bear fruit ...
Breaking Biology News(10 mins):Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5Scientists identify natural anti-cancer defenses 2New management methods extend blackberry season 2APhA Welcomes New Leader 50588 1APhA Welcomes New Leader 50588 2APhA Welcomes New Leader 50588 3As Fire Ants Continue to Proliferate Hospital Proven Burn Anesthetic Brings Instant Relief for Bites Stings 50584 1As Fire Ants Continue to Proliferate Hospital Proven Burn Anesthetic Brings Instant Relief for Bites Stings 50584 2New Mexico Supreme Court Ruling Enhances Air Ambulance Safety 50580 1New Mexico Supreme Court Ruling Enhances Air Ambulance Safety 50580 2
... to be sperm or eggs , Johns Hopkins biologists have ... to develop into a male's sperm or a female's eggs. ... are the precursors to both sperm and eggs. Unable to ... must take "advice" from other cells within embryos as to ...
... New research has shown that combinations of chemicals found ... damaging effects on sperm fertility. , Professor Lynn Fraser ... of Human Reproduction and Embryology today (Wednesday), that her ... mimic the female sex hormone, oestrogen, could individually affect ...
... Johns Hopkins Bloomberg School of Public Health have developed ... cell extracts of microorganisms using traditional peptide mass fingerprinting ... the researchers, is a "shortcut" for preparing samples that ... cost of protein identification, they believe PMF can become ...
Other Biology News:Decisions, decisions: Male or female? 2Environmental chemical cocktail may sabotage sperm 2Environmental chemical cocktail may sabotage sperm 3Researchers develop new method for facile identification of proteins in bacterial cells 2
... A.D. Smith et.al. (1997) ... entries on current biochemistry & ... than 17,000 headwords. Entries give ... the processes in which they ...
...
...
... • Rhesus serum is collected from fasted ... of age. Available Anticoagulants: ... N-06: K2EDTA N-08: Potassium ... Alsevers N-05: ACD N-07: ...
Biology Products: